(Project 2) Metastatic castrate resistant prostate cancer (mCRPC) in bone is almost universally fatal. While new targeted therapeutics have improved patient survival, resistance invariably develops. Treatment refractory bone metastases lead to morbidity and mortality in patients with mCRPC. Long-term goals of this proposal are to understand mechanisms of therapy resistance and strategies to overcome them. Studies of this proposal focus on resistance mediated from the bone microenvironment. Specifically, using an osteogenic prostate cancer xenograft, MDA-PCa-118, we found that treatment with cabozantinib, an oral multi-kinase inhibitor with potent activity against p-MET and p-VEGFR-2, demonstrated striking initial responses. However, resistance rapidly occurs, as first evidenced by viable cells tumor cells found in proximity to newly formed bone matrix. Because prostate cancer bone metastasis presents with a unique bone-forming phenotype, we hypothesize that factors released from tumor-induced bone lead to pre-existing resistance, in which the microenvironment has already contributed factors that mediate resistance prior to application of therapy. To study the mechanisms of this form of resistance, a secretome analysis was performed on conditioned medium from prostate cancer-induced bone, which identified 121 bone-secreted proteins. Many of these bone-secreted proteins activate integrins through paracrine effects, increasing tumor cell survival. We term these osteoblast-secreted paracrine factors ?osteocrines?. Consistent with the involvement of integrins in therapy resistance, we found that FAK, the downstream effector of integrin signaling, is highly activated in therapy-resistant tumor cells. Thus, we hypothesize that osteocrines released from prostate cancer-induced bone form a pre-existing resistance niche that mediates therapy resistance of prostate cancer cells through activation of FAK. We will test this hypothesis by: (1) Examining the ability of selected osteocrines to confer therapy resistance through activation of FAK; (2) Examining the effects of second-generation FAK inhibitors (VS-6063 or VS- 4718) on overcoming osteocrine-induced therapy resistance in xenograft mouse models; and (3) Conducting a clinical trial to examine the toxicity and efficacy of a FAK inhibitor (VS-6063 or VS-4718) in men with treatment- refractory bone-metastatic castrate-resistant prostate cancer. The studies would be paradigm shifting by demonstrating that the tumor microenvironment can provide a niche of ?pre-existing resistance?, a mechanism of resistance in addition to tumor adaptation to therapy, which is likely applicable to multiple therapies in mCRPC. The studies would also demonstrate the potential efficacy of FAK inhibitors for treatment of bone-metastatic CRPC. In addition, delineating mechanisms of this ?pre-existing resistance? will provide new predictive markers to guide therapeutic strategies to overcome resistance.

Public Health Relevance

(Project 2) While several new therapeutic agents have prolonged the lives of men with metastatic castrate resistant prostate cancer (mCRPC), resistance invariably develops, leading to death. This proposal tests the novel concept that newly formed bone induced by metastatic prostate cancer cells forms a ?resistance niche? by releasing ?osteocrines,? soluble molecules that confer resistance to therapies for mCRPC. Inhibitors that block osteocrine-induced resistance will prolong survival of men with mCRPC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140388-08
Application #
9542257
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
8
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Wang, Hong; Yang, Xu; Liu, Anna et al. (2018) ?-Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten-/- mice. Carcinogenesis 39:158-169
Velazquez-Torres, Guermarie; Shoshan, Einav; Ivan, Cristina et al. (2018) A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun 9:461
Zanoaga, Oana; Jurj, Ancuta; Raduly, Lajos et al. (2018) Implications of dietary ?-3 and ?-6 polyunsaturated fatty acids in breast cancer. Exp Ther Med 15:1167-1176
Zhang, Wei; Liu, Bo; Wu, Wenhui et al. (2018) Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24:696-707
Monroig-Bosque, Paloma Del C; Shah, Maitri Y; Fu, Xiao et al. (2018) OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Sci Rep 8:13106
Basourakos, Spyridon P; Davis, John W; Chapin, Brian F et al. (2018) Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int 121:69-76
Pan, Tianhong; Lin, Song-Chang; Yu, Kai-Jie et al. (2018) BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia 20:32-43
Yu-Lee, Li-Yuan; Yu, Guoyu; Lee, Yu-Chen et al. (2018) Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGF?RIII-p38MAPK-pS249/T252RB Pathway. Cancer Res 78:2911-2924
Luo, Yong; Azad, Abul Kalam; Karanika, Styliani et al. (2018) Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. Int J Cancer 142:2163-2174
Soundararajan, Rama; Aparicio, Ana M; Logothetis, Christopher J et al. (2018) Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Front Oncol 8:69

Showing the most recent 10 out of 217 publications